Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Two Rabbit Monoclonal Antibodies Released for Cancer Diagnosis

By LabMedica International staff writers
Posted on 14 May 2014
A provider of cancer diagnostic solutions announced the addition of two new antibodies, Anti-CK 8/18 and Anti-TdT, to a portfolio of high-quality reagents, instruments, and software.

Anti-CK 8/18 is the first rabbit monoclonal antibody cocktail for cytokeratin 8/18 (CK 8/18) available from a major pathology provider. More...
It is used by pathologists to stain CK 8/18 in tissue samples and thereby help classify tumors of unknown origin. Keratins are one of the most potent epithelial differentiation and tumor markers in cancer diagnostics.

Anti-TdT, also a rabbit monoclonal antibody, is used to help classify lymphoma and leukemia by staining terminal deoxynucleotidyl transferase (TdT) in tissue samples. In immunohistochemistry, antibodies to TdT can be used to demonstrate the presence of pre-T and pre-B cells and multipotent hematopoietic stem cells that possess the antigen.

Both antibodies are available from Dako now as 1.0 mL concentrates and 12 mL (60 tests).

Dako (Glostrup, Denmark) released the antibodies Anti-CK 8/18 and Anti-TdT, which provide good specificity and sensitivity, and have been evaluated and accepted by pathologists. Both antibodies provide optimal staining results with the FLEX ready-to-use Dako solutions. FLEX ready-to-use is a plug-and-play solution consisting of pre-diluted antibodies, a visualization system, and optimized validated protocols developed in collaboration with pathologists. The protocols are developed to take into account pre-analytical variations and different ways of processing and handling tissue samples, ensuring optimal staining results for pathology labs.

Hans Christian Pedersen, global product manager, Dako said, "With the FLEX RTU solution, it takes less time for a lab to validate new antibodies for routine diagnostic use. FLEX ready-to-use antibodies are helping labs get high-quality results from day one."

"We are pleased to add these two high-quality antibodies to our comprehensive offering to pathologists around the world," said Britt Meelby Jensen, vice president of marketing and pathology sales in Agilent's diagnostics and genomics business. "One of our goals is to constantly establish new quality benchmarks within IHC reagents."

Agilent Technologies Inc. (Santa Clara, CA, USA) is a measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics, and communications. In 2012, it acquired Dako a provider of reagents, instruments, software, and expertise to make accurate diagnoses and determine the most effective treatment for cancer patients.

Related Links:

Dako

Agilent



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.